Regulus Therapeutics (RGLS) Misses Q3 EPS by 4c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Westport Fuel Systems (WPRT) Misses Q2 EPS by 64c
• National CineMedia (NCMI) Misses Q2 EPS by 7c
• Optex Systems Holdings, Inc. (OPXS) Misses Q3 EPS by 2c